Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested ...
Novartis stock rose Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...
Ionis Pharmaceuticals (IONS) stock slips as Novartis (NVS) delays Phase 3 trial data for its cardiac therapy pelacarsen. Read more here.
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...
J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
In the corporate sector, Novartis (SIX: NOVN) stock rose 4% after Swiss drugmaker reported strong fourth-quarter results ...
Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it had net income of $1.41. Earnings, adjusted for ...
Looking ahead to 2025, Novartis maintains an optimistic stance, forecasting mid to high single-digit sales growth and anticipating even stronger operational core earnings in the high single to low ...